---
title: "Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Hold from HSBC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292545972.md"
description: "HSBC maintained a Hold rating on Shanghai Fosun Pharmaceutical (Group) Co with a HK$18.30 price target in a July 10 report, while shares closed at HK$16.34. Conversely, TipRanks data shows an analyst consensus of Moderate Buy for the company, with a higher consensus price target of HK$25.24."
datetime: "2026-07-14T00:27:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292545972.md)
  - [en](https://longbridge.com/en/news/292545972.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292545972.md)
generator: "portal-rs"
---

# Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Hold from HSBC

In a report released on July 10, from HSBC maintained a Hold rating on Shanghai Fosun Pharmaceutical (Group) Co, with a price target of HK$18.30. The company’s shares closed last Tuesday at HK$16.34.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Shanghai Fosun Pharmaceutical (Group) Co has an analyst consensus of Moderate Buy, with a price target consensus of HK$25.24.

### Related Stocks

- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [HSBH.US](https://longbridge.com/en/quote/HSBH.US.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)

## Related News & Research

- [REG - Informa PLC HSBC Holdings PLC - Holding(s) in Company](https://longbridge.com/en/news/298010785.md)
- [HSBC Continues Share Buy-Back With Further UK and Hong Kong Purchases](https://longbridge.com/en/news/297709260.md)
- [HSBC Advances Share Buy-Back With Further UK and Hong Kong Repurchases](https://longbridge.com/en/news/297967951.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [3 'Outperform' ETFs with 10%+ Upside Potential, According to the AI Analyst](https://longbridge.com/en/news/297964242.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**